FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin

The U.S. Food and Drug Administration's staff said on Wednesday the use of Novo Nordisk's (NOVOb.CO) long-acting weekly insulin had an increased risk of low blood sugar in patients with type 1 diabetes, who are more insulin-dependent.